Extended-Interval Dosing of Natalizumab Is Associated With Reduced PML Risk
In the TOUCH Prescribing Program, patients with extended dosing intervals were less likely to develop progressive multifocal leukoencephalopathy.
Neurology Reviews. 2018 April;26(4):35
April 3, 2018|Multiple Sclerosis Hub
—Fred Balzac
Suggested Reading
Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord. 2014;7(5):227-231.
Fine AJ, Sorbello A, Kortepeter C, et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol. 2014;75(1):108-115.
Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925-933.
Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(8):885-889.
